Perbak Capital Partners LLP Increases Stake in Twist Bioscience Corporation $TWST

Perbak Capital Partners LLP boosted its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 96.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,415 shares of the company’s stock after buying an additional 22,805 shares during the quarter. Perbak Capital Partners LLP owned 0.08% of Twist Bioscience worth $1,306,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience in the second quarter valued at $97,000. CWM LLC boosted its holdings in Twist Bioscience by 61.4% in the third quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after purchasing an additional 1,648 shares during the period. AXQ Capital LP purchased a new position in Twist Bioscience in the second quarter valued at $226,000. Finally, Bayesian Capital Management LP acquired a new position in Twist Bioscience during the 2nd quarter worth $253,000.

Twist Bioscience Stock Up 0.6%

Twist Bioscience stock opened at $43.28 on Friday. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $57.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The stock has a market cap of $2.65 billion, a PE ratio of -33.81 and a beta of 2.23. The stock’s fifty day moving average is $44.94 and its two-hundred day moving average is $35.17.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. On average, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on TWST shares. Robert W. Baird set a $50.00 price target on Twist Bioscience in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Barclays upped their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. Evercore raised their target price on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Finally, TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Insider Activity

In related news, CFO Adam Laponis sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the transaction, the chief financial officer directly owned 130,031 shares of the company’s stock, valued at $6,501,550. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jan Johannessen sold 2,200 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $47.91, for a total transaction of $105,402.00. Following the completion of the transaction, the director owned 17,754 shares in the company, valued at $850,594.14. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 40,392 shares of company stock valued at $1,840,796 over the last 90 days. Insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.